The traveler’s diarrhea treatment market is expected to witness robust growth due to a surge in the number of travelers, rising awareness among travelers, and the availability of over-the-counter medications.
Key Highlights
- Traveler’s diarrhea affects millions of international travelers who travel to developing countries each year. Food and contaminated water are the primary sources of infection. Bacteria, such as E. coli and Salmonella, are the common causes of traveler’s diarrhea.
- According to the World Tourism Organization (UNWTO), in 2019, around 1.5 billion international tourist arrivals were recorded, which was a 4% rise from 2018. The prevalence of traveler’s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. The travel destination is the most significant risk factor for traveler’s diarrhea.
- Hence, owing to these factors, the market is likely to witness significant growth during the forecast period. However, the side effects associated with the drugs are expected to impede the market growth.
Key Market Trends
The Retail Pharmacies Segment is Expected to Show Better Growth in the Forecast Years
Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. A retail pharmacy refers to an independent pharmacy that has a state license to dispense medications to the general public. People are increasingly adopting retail pharmacies as a one-stop-shop to buy medicines. They are highly preferred by people who are unable to reach hospitals for a check-up on a regular basis and need medicine for quick treatment. The better outreach of retail pharmacies makes them a highly profitable segment and the most established one across several countries. Furthermore, the surge in the number of travelers is also expected to fuel the market growth during the forecast period.
North America Holds the Largest Share in the Market
The North American region holds the largest share of the market due to the increasing burden of traveler’s diarrhea and strong presence of manufacturers in this region. The rising awareness, along with the easy availability of over-the-counter medications, is likely to favor the growth of the traveler’s diarrhea treatment market in North America. However, the side effects associated with the drugs are likely to impede the growth of the market during the forecast period.
Competitive Landscape
The market studied is moderately competitive, and there are several global companies that are operating in this market. The major players in the traveler’s diarrhea treatment market are Bausch Health Companies Inc. (Salix Pharmaceuticals), Bristol-Myers Squibb Company, Cosmo Pharmaceuticals NV, Immuron Limited, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Sanofi SA, and Valneva Canada Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bausch Health Companies Inc. (Salix Pharmaceuticals)
- Bristol-Myers Squibb Company
- Cosmo Pharmaceuticals NV
- Immuron Limited
- Johnson & Johnson
- Pfizer Inc.
- Procter & Gamble
- Sanofi SA
- Valneva Canada Inc.
Methodology
LOADING...